Business Context and Reporting Period
This Form 8-K was filed by Viking Therapeutics, Inc. on January 19, 2018. The report addresses Item 5.02 regarding compensatory arrangements for certain officers. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation adjustments.
- CEO Bonus (Brian Lian, Ph.D.): $110,000
- CFO Bonus (Michael Morneau): $52,500
- Recalculated CEO Total Compensation (FY 2017): $866,946
- Recalculated CFO Total Compensation (FY 2017): $485,830
Material Changes Versus Prior Period
The filing discloses a material update to executive compensation figures previously reported in the Company's Registration Statement on Form S-1 (filed January 9, 2018). The bonuses were not included in the initial S-1 filing because the amounts were not determined or calculable at that time. The Compensation Committee approved these payments on January 19, 2018, based on the achievement of 2017 corporate performance objectives.
Guidance, Outlook, and Risks
The filing contains no guidance, outlook, or discussion of risks and contingencies. The unusual item reported is the retroactive inclusion of performance bonuses for the 2017 fiscal year into the executive compensation totals.
Key Facts for Investor Verification
- Verify the updated total compensation figures for the CEO and CFO in the Company's most recent proxy statement or S-1 amendment.
- Confirm the specific corporate performance objectives adopted in March 2017 that triggered these bonus payments.
- Note that the CEO received 50% of his target bonus and the CFO received 50% of his target bonus for the 2017 program.